Profiles in Business - May 28, 2019
Hey there, Alex Haahr Gouliaev
Nordic Life Science asked the CEO of Nuevolution about the offer from Amgen to buy Nuevolution for $166.8 million. Nuevolution’s pipeline and selective deal-making approach has recently proven to be both solid and successful, with presentations of progress in multiple projects, and last week, Amgen made an offer. What’s your comment about the Amgen offer? “The […]
Acquisition - May 24, 2019
Amgen to buy Nuevolution for $166.8 million
Amgen has agreed to buy the biopharmaceutical company Nuevolution AB for 1.61 billion Swedish crowns ($166.8 million) to boost its position in drug discovery. Nuevolution said its board unanimously recommended Amgen’s cash offer of 32.5 Swedish crowns per share, a premium of 168.6% to Nuevolution’s closing price on Tuesday, reported Reuters. The offer from Amgen […]
Pharma Business - January 4, 2018
Nuevolution will receive license fee payment of SEK 6.11 million
Nuevolution announces that Janssen Biotech has exercised its option to license one of the research programs under the multi-target collaboration entered between the parties in October 2015, a collaboration that was expanded further in April 2016 and March 2017. The program that has been licensed to Janssen Biotech relate to a disease target in the therapeutic area of anti-infectives. […]
Pharma Business - March 6, 2017
Nuevolution announces further technology access fee payment
Nuevolution announces that Janssen Biotech has used its option to expand the collaboration with Nuevolution, thereby providing Nuevolution with a technology access fee payment of 600,000 USD (SEK 5.45 million). Nuevolution A/S and Janssen entered into collaboration on 19 October 2015 for application of Nuevolution’s proprietary Chemetics drug discovery platform against biological disease targets of […]
Collaboration - January 25, 2017
Nuevolution in scientific article with Nobel Laureate
Nuevolution announces the publication of the scientific article entitled “An allosteric “Beta-Blocker” isolated from a DNA-encoded small molecule library” in the Proceedings of the National Academy of Sciences, USA. The article presents work from the ongoing collaboration between Nuevolution and the group of Nobel Laureate Dr. Robert J. Lefkowitz at Duke University involving the screening […]
Collaboration - October 3, 2016
Nuevolution announces strategic collaboration
Amgen and Nuevolution have entered into a multiple target research collaboration to develop and commercialize novel therapeutics in the areas of oncology and neuroscience. Nuevolution will apply its Chemetics drug discovery platform to discover and advance potential therapeutics of interest to Amgen. The research collaboration brings together Nuevolution’s proprietary drug discovery platform with Amgen’s disease […]
